Ex-Alere execs plan buyout
This article was originally published in Clinica
Executive Summary
A group led by ex-Alere CEO Ron Zwanziger has made a move to buy the beleaguered company, for an estimated price of $3.82bn. Mr Zwanziger, who resigned unexpectedly from Alere in July, made a Schedule 13D filing with the US Securities and Exchange Commission (SEC) saying the group intends to make an offer of $46 per share for Alere, or possibly higher, and requesting a month-long due diligence period.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.